Argos Therapeutics Inc.: Argos Therapeutics to Hold First Quarter 2014 Financial Results Conference Call on Tuesday, May 13, 2014

Tickers: ARGS
DURHAM, N.C., April 29, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's first quarter 2014 financial results will be released after market close on Tuesday, May 13, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 34954627. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014.www.argostherapeutics.com.

CONTACT: Investors:

         Angeli Kolhatkar

         Burns McClellan

         akolhatkar@burnsmc.com

         (212) 213-0006

         

         Media:

         Bill Berry

         Berry & Company Public Relations

         bberry@berrypr.com

         (212) 253-8881
distributed by

This noodl was issued by Argos Therapeutics Inc. and was initially posted at www.argostherapeutics.com. It was distributed, unedited and unaltered, by noodls on 2014-04-29 15:11:25 CET. The issuer is solely responsible for the accuracy of the information contained therein.